Evidence map›Paper›PMID 32843432›Full record

ArticleCold Spring Harbor molecular case studies2020

Successful BRAF/MEK inhibition in a patient with

Elena Busch, Simon Kreutzfeldt, Abbas Agaimy, Gunhild Mechtersheimer, Peter Horak, Benedikt Brors, Barbara Hutter, Martina Fröhlich, Sebastian Uhrig, Philipp Mayer and 7 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cold Spring Harbor molecular case studies, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Characteristics ofTherapeutic advances in medical oncology · 2025
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Remarkable response ofGastroenterology report · 2022
    Article
  10. Article
  11. Next-generation therapies for pancreatic cancer.Expert review of gastroenterology & hepatology
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Elena Busch *Department of Medical Oncology, University Hospital Heidelberg, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, 69120, Germany.
Simon Kreutzfeldt *Department of Translational Medical Oncology, NCT Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany.
Abbas AgaimyInstitute of Pathology, University Hospital Erlangen, Erlangen, 91054, Germany.
Gunhild MechtersheimerInstitute of Pathology, University Hospital Heidelberg, Heidelberg, 69120, Germany.
Peter HorakDepartment of Translational Medical Oncology, NCT Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany.ORCID 0000-0003-4536-9306
Benedikt BrorsDivision of Applied Bioinformatics, DKFZ and NCT Heidelberg, Heidelberg, 69120, Germany.
Barbara HutterDivision of Applied Bioinformatics, DKFZ and NCT Heidelberg, Heidelberg, 69120, Germany.
Martina FröhlichDivision of Applied Bioinformatics, DKFZ and NCT Heidelberg, Heidelberg, 69120, Germany.
Sebastian UhrigDivision of Applied Bioinformatics, DKFZ and NCT Heidelberg, Heidelberg, 69120, Germany.
Philipp MayerDepartment of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, 69120, Germany.
Evelin SchröckNCT Partner Site Dresden, University Cancer Center (UCC) Dresden, Dresden, 01307, Germany.
Albrecht StenzingerInstitute of Pathology, University Hospital Heidelberg, Heidelberg, 69120, Germany.
Hanno GlimmNCT Partner Site Dresden, University Cancer Center (UCC) Dresden, Dresden, 01307, Germany.
Dirk JägerDepartment of Medical Oncology, University Hospital Heidelberg, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, 69120, Germany.
Christoph SpringfeldDepartment of Medical Oncology, University Hospital Heidelberg, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, 69120, Germany.
Stefan FröhlingDepartment of Translational Medical Oncology, NCT Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany.
Stefanie ZschäbitzDepartment of Medical Oncology, University Hospital Heidelberg, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, 69120, Germany.
Heidelberg University · DEGerman Cancer Research Center · DEUniversity Cancer Center Hamburg · DEUniversitätsklinikum Erlangen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic acinar cell carcinoma (PAC) is a rare disease with a poor prognosis. Treatment options for metastatic PAC are limited and often follow chemotherapeutic regimens for pancreatic ductal adenocarcinoma. Although recurrent genomic alterations, such as

Indexed as

AdultAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Acinar CellHumansMaleMAP Kinase Kinase 1Mitogen-Activated Protein Kinase KinasesMutationPancreatic NeoplasmsPrecision MedicineProtein Kinase InhibitorsProto-Oncogene Proteins B-rafBRAF protein, humanMAP2K1 protein, humanMAP Kinase Kinase 1Mitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafneoplasm of the pancreas

Identifiers

PMID32843432
PMCPMC7476408
OpenAlexW3081218277

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.